Clinical correlative studies have linked 1p36 deletions with worse prognosis in follicular lymphoma (FL). In this study, we sought to identify the critical gene(s) in this region that is responsible for conferring inferior prognosis. BAC array technology applied to 141 FL specimens detected a minimum region of deletion (MRD) of ~97 kb within 1p36.32 in 20% of these cases. Frequent SNP-detected copy-neutral loss of heterozygosity was also found in this region. Analysis of promoter CpGs in the MRD did not reveal differential patterns of DNA methylation in samples that differed in 1p36 status. Exon sequencing of MRD genes identified somatic alterations in the TNFRSF14 gene in 3/11 selected cases with matching normal DNA. An expanded cohort consisting of 251 specimens identified 46 cases (18.3%) with nonsynonymous mutations affecting TNFRSF14. Overall survival (OS) and disease-specific survival (DSS) were associated with the presence of TNFRSF14 mutation in patients whose overall treatment included rituximab. We further demonstrated that inferior OS and DSS were most pronounced in patients whose lymphomas contained both TNFRSF14 mutations and 1p36 deletions after adjustment for the International Prognostic Index (HR=3. 65, p=0.011 and HR=3.19, p=0.039, respectively).
Introduction
Follicular lymphoma (FL) is characterized at the karyotype level by the t(14;18)(q32;q21) that leads to overexpression of the anti-apoptotic gene BCL2 due to relocation in proximity to the IGH enhancer (1) (2) (3) (4) (5) (6) . In the great majority of cases additional chromosomal changes are evident, some of which represent diseaseassociated events of clonal evolution. Alterations resulting in deletion of chromosome band 1p36 constitute the most frequent of these secondary karyotypic alterations. The 1p36 region has been the focus of attempts to refine the deletion breakpoints and identify driver or tumor suppressor gene(s), but historically, these efforts have been hampered by relatively small sample cohorts, the inclusion of heterogeneous subtypes of lymphoma and the low resolution of analytic tools available including standard cytogenetic analysis and chromosome-based comparative genomic hybridization (CGH). Most of these studies have reported 1p36 aberrations in the form of intrachromosomal deletions and unbalanced translocations (7-10). Recently developed high resolution technologies have shed further light on the issue. Of interest, a study by Ross et al of 58 FL cases analyzed using a 50k single nucleotide polymorphism (SNP) array demonstrated that 50% of these cases had either copy number loss or copyneutral loss of heterozygosity (cnLOH) at 1p36 (5) . O'Shea et al, using a lower resolution 10k SNP assay, found 8% of cases to show cnLOH but found no evidence of deletions, possibly due to the low resolution capability of the array, however, correlation between 1p36 cnLOH and overall survival (OS) was significant (11). These studies have highlighted the importance of alternate mechanisms of gene inactivation that may 4 be operative in FL. Although the affected region of alteration identified in these studies was still relatively large at 8.5Mb (5), a specific candidate gene was not identified.
In a previous study we have demonstrated by karyotype and array CGH that a region of ~11 Mb from 1p36.22 to p36.33 was deleted at a frequency of ~25% in 106 FL specimens and the deletion was shown to correlate with risk for development of transformed diffuse large B cell lymphoma (DLBCL) and for poor survival outcome independent of clinical risk predictors (6) . In this study we have applied tiling path BAC array CGH, with a resolution of 80-150 kb (12), to a larger cohort of 141 FL specimens and applied robust computational algorithm to further fine-map the 1p36 deleted region.
We have also used a custom-designed oligonucleotide microarray targeted to band 1p36, promoter methylation analysis and exon sequencing to identify the potential gene of interest. Further, in an expanded cohort of 251 FL patients, we have assessed the frequency and clinical impact of somatic mutations of a candidate gene in the 1p36 region.
Materials and Methods

Patient materials
For breakpoint mapping of 1p36 deletions, 141 FL cases were selected from the Lymphoid Cancer Database of the British Columbia Cancer Agency diagnosed between 1987 and 1996 based on the availability of sufficient frozen tumor material for DNA extraction. 103 of these 141 cases were included in a previous study (6) Cytogenetic analysis of lymph node specimens was performed as previously described (8). FISH was performed on residual cell suspensions using the LSI IGH/BCL2 probe according to the manufacturer's protocol (Vysis, Downers Grove, IL, USA) to detect the presence of IGH/BCL2 genomic fusion. For validation of deletion of the 1p36.32 locus, the BAC clones RP13-493G06, RP13-586E24 and RP11-756P03 were selected from the array CGH profile and prepared for use as FISH probes as previously described (14) . BAC RP11-229M05 at 1q32.3 was used as a copy number control. All BAC clones had previously been identity-verified by BAC-end sequencing and by hybridization to normal metaphases to confirm the expected site of chromosomal localization. The frequency of false deletion for each BAC FISH probe was established by hybridization to normal lymphocyte cell suspensions and ranged from 0.5 to 3.0%.
For the purpose of this study the cut-off value for true deletion was set at >5% of 200 interphase nuclei. All of the FISH studies were performed on residual methanol-acetic acid preserved cell pellets.
Sample preparation
Genomic tumor DNA was extracted from frozen tissue or frozen cell suspensions using the ALLPREP kit (Qiagen, Germany). Germline DNA was extracted from peripheral blood in 11 patients using PureGene DNA purification kit (GENTRA, MN).
BAC array CGH and oligonucleotide array analysis
The sub-megabase resolution tiling (SMRT) BAC array contains 26,819 BAC clones spotted in duplicate on glass slides and covers >95% of the human genome (15, 16) .
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Array CGH using this platform was performed as previously described (17) . A custom built high density Agilent oligonucleotide array was designed using the eArray software (Agilent Technologies, Santa Clara, CA) and contained ~12,000 60-mer probes with an average of one probe per 500 basepairs spanning the first 5,983,478 bp of the 1p terminus. Hybridization to the custom Agilent array was performed using 500 ng of tumor DNA according to the manufacturer's protocol (Agilent Technologies). Analysis of BAC array CGH data was performed using the joint inference Hidden Markov Model called Conditional Markov Model (CMM) proposed by Colella et al, adapted for array CGH to detect subtle clone shifts in recurrent cases (18) . The model consists of a nonstationary transition matrix indexed by a probe that is shared across samples, thus allowing for borrowing statistical strength that may be present in recurrent alterations.
Data from the Agilent oligo array were visualized using the CGHAnalytics 3.0 software (Agilent Technologies) and analyzed using the supplied statistical algorithm ADM-1 with sensitivity threshold set to 5.0, the moving average window to 1 Mb, and the requirement of 10 consecutive probes to annotate a loss or a gain.
DNA methylation analysis
CpG's were selected for pyrosequencing based on their location within the promoter of the associated gene. Specifically, if the gene had a CpG island promoter, CpG's from within the island were chosen. If the gene did not have an identified CpG island promoter, CpG's closest to the transcription start site were chosen. PCR primer and sequencing primer design were performed using the PyroMark software (Qiagen).
Genomic DNA (500 ng) was bisulfite-converted using the EZ DNA Methylation Gold Kit then prepared for pyrosequencing as described by Tost and Gut (19) using the PyroMark reagent kit (Qiagen) and sequencing primers as listed in Supplemental Table   1 . Pyrosequencing was performed using a PyroMark Q96 ID instrument (Qiagen) and bisulfite DNA conversion was confirmed using internal bisulfite conversion controls.
DNA Sequencing
Exon sequencing was performed using an ABI 3730xl DNA analyzer and the Jumpstart Table 1 .
Statistical analysis
Statistical analyses were performed using SPSS Software version 14.0. For methylation analysis, differences among groups were evaluated by one-way ANOVA. Pearson ChiSquare test was used to determine the significance of any differences between the clinical variables in mutated versus wild type samples. Survival curves were plotted using the Kaplan-Meier method and compared using the log-rank test. OS was defined as the time from diagnosis to date of most recent follow-up (censored) or death from any cause (event). The Cox Proportional hazards model that included the International Prognostic Index (IPI) Score was used to determine the significance of variables in the univariate survival analyses. All statistical tests were two-sided and considered significant at p ≤ 0.05.
Results
Identification of the Minimum Region of Deletion on 1p36
In a previous study we demonstrated a deletion frequency of ~25% at chromosome band 1p36 based on the BAC array CGH analysis of 106 diagnostic FL biopsies (6). (1p36: red arrowhead; 1q32 control: green arrowhead). All deletions detected by array CGH were validated by FISH analysis using one or more of the BAC probes RP13-493G06, RP13-586E24 and RP11-756P03 with probe RP11-229M05 mapping at 1q32.3 as a copy number control. The majority of the deletions were shown to be heterozygous, while two were homozygous. High resolution oligonucleotide array analysis was performed on case #1, which had the smallest array CGH-detected 1p36 deletion, to fine-map the breakpoints (left panel of Figure 1B ). Due to numerous sequence repeats in this area a portion of the deleted region was not covered by the probes, however, the deletion spanned 224,674 bp containing the five genes identified in the MRD by array CGH analysis (red/black/blue dots are data points representing gain/neutral/loss status).
The MRD region was also examined with Affymetrix mapping 500k SNP arrays to detect possible cnLOH using 27 selected cases with available matched germline DNA (from the 141 cases used to determine the MRD). Six of the 27 cases (22.2%) showed cnLOH affecting chromosome arm 1p with an overlapping region of cnLOH of approximately 15Mb that included the 97 kb-MRD identified by array CGH (data not shown).
Methylation Status of Genes in the MRD
The methylation pattern of four of the five genes within the MRD was investigated using the pyrosequencing technique (Figure 2 ). Technical failures prevented the analysis of LOC115110, due likely to abundant sequence repeats in the promotor region (see Figure 2) . A number of samples were not investigated due to the lack of available tumor 
Validation of TNFRSF14 Mutation Frequency and Correlation with Inferior Prognosis
To determine the frequency of TNFRSF14 mutation and to undertake clinical correlative analysis, we selected 115 cases with sufficient DNA from our 141 discovery cohort (used in determining the MRD and for which 1p36 deletion status was known) plus 136 additional FL specimens from our archive in which 1p36 deletion status was not known, totaling 251 primary FL cases. The clinical features and mutation findings for these cases are summarized in Tables 1 and 2 
TNFRSF14.
On examination of the relationship between 1p36 deletion and TNFRSF14 mutation, we found in the 114 cases where both deletion status and mutation status was known, eight cases (7%) were positive for both 1p36 deletion and TNFRSF14 mutation, 10 cases (8.8%) were TNFRSF14 mutation positive and 1p36 deletion negative, and 23 cases (20.2%) were 1p36 deletion positive and TNFRSF14 mutation negative. The clinical impact of these findings is presented below. Furthermore, we found that among the 35 cases with paired specimens taken at diagnosis and later at the time of development of transformed DLBCL, a TNFRSF14 mutation was detected in both samples from five paired specimens and in two of the transformed samples where the corresponding prior FL samples had no mutation.
Analysis of clinical correlation with TNFRSF14 mutations in an expanded cohort of 251 cases revealed that TNFRSF14 mutations were associated with high-risk clinical features (see Table 1 ). Specifically, patients with mutated TNFRSF14 were more likely to have a poor performance status and their FL involved a greater number of extranodal sites. When patients, whose overall treatment included rituximab, were analyzed, inferior OS and disease-specific survival (DSS) were observed in those with a mutation in TNFRSF14 (median 3.73 years and 7.52 years, respectively) compared to those without (median 15.85 years and 15.85 years) (log-rank test, p<0.001 and p=0.004, respectively) ( Figure 3A and B) . On multivariate analysis using Cox regression, Patients with one alteration ("mut or del"; median 7.52 years) or both alterations ("mut/del"; median 6.09 years) displayed a significantly inferior OS compared to those without either alteration ("no mut/no del"; median 11.23 years) or cases without any mutation but in whom the 1p36 deletion status was unknown ("no mut/del NA"; median 11.69 years) (log-rank test, p=0.005) (see Figure 3C) . On multivariate analysis, cases with both aberrations (1p36 deletion and TNFRSF14 mutation) remained a significant predictor of OS independent of the IPI compared to the group of no aberrations (HR=3.65, 95% CI 1.35-9.878, p=0.011). In the analysis of DSS, patients with both alterations ("mut/del"; median 7.61 years) displayed a significantly inferior DSS compared to those without either alteration ("no mut/no del"; median 11.23 years), those with one alteration ("mut or del"; median not reached), or cases without any mutation but in whom the 1p36 deletion status was unknown ("no mut/del NA"; median not reached) (log-rank test, p=0.037) (see Figure 3D ). Cases with both aberrations (1p36 deletion and TNFRSF14 mutation) remained a significant predictor independent of the IPI compared to the group of no aberrations (HR=3.19, 95% CI 1.06-9.57, p=0.039).
Discussion
Based on microarray-based copy number and cnLOH data analyses, we have identified 
tumor and constitutional DNA revealed that only TNFRSF14 was affected by acquired somatic mutations in the clonal cells. In the cohort of 251 cases where matching constitutional DNA was not examined, 47 nonsynonymous mutations were detected in 46 cases (18.3%) (after elimination of known polymorphic variants).
Although the mutations detected in the 251 case study were not definitively confirmed to be somatic by parallel constitutional DNA sequencing, the lack of similar mutations in large public genomic databases and the significant correlation of these observed mutations with inferior clinical outcomes provide strong evidence that these mutations are somatic in nature and that TNFRSF14 is the target gene in the 1p36 MRD.
In the clinical correlative analysis of the 251 patient cohort, we report three interesting observations. First, patients with TNFRSF14 mutations were more likely to have highrisk clinical features such as poor performance status and involvement of multiple extranodal sites. Second, TNFRSF14 mutation alone or combined with 1p36 deletion correlated with inferior prognosis. Third, the adverse impact of TNFRSF14 mutation on FL patients was independent of rituximab treatment. The implications of these findings are of clinical significance. Essentially, there appears to be a dose effect where homozygosity for a somatic TNFRSF14 gene defect (deletion plus mutation) was correlated with the poorest clinical outcomes. In addition, treatment with rituximab conferred less than expected benefit in patients with a mutation in TNFRSF14.
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